abc7NY42m
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
JMP reiterates Kalvista stock with $19 target, sees market growth
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
Going to court is never fun, but here’s why we sued the state
The Indiana Capital Chronicle sued the Indiana Department of Correction (IDOC) last week — a move we as an outlet don’t take ...
AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make ...
Hays Post1h
Local pharmacies closings across state for advocacy day; learn why, see where
Independent pharmacies across Kansas will close on Wednesday, Feb.5, for a day of advocacy to raise awareness of what they ...
Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
Knowridge3h
This drug protects heart and kidneys in type 2 diabetes
The study offers promising news for people with type 2 diabetes. By using SGLT2 inhibitors, they may be able to lower their ...
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.